STAT2 Knockout Syrian Hamsters Support Enhanced Replication and Pathogenicity of Human Adenovirus, Revealing an Important Role of Type I Interferon Response in Viral Control

English version České info

The biology of human adenoviruses has been studied extensively; however, much less is known about the replication and pathogenesis of the virus in a permissive host. Our laboratory pioneered the use of Syrian hamsters to study the pathogenesis of human adenoviruses. Syrian hamsters are permissive for species C human adenoviruses, which replicate in these animals and cause illness akin to that in humans. Hereby, we report findings with a new Syrian hamster strain (STAT2 KO hamsters), in which the Type I interferon pathway, an important part of the innate immune response to virus infection, is disrupted. This is the first genetically modified Syrian hamster strain ever reported. We show that these animals are very sensitive to infection with type 5 human adenovirus (Ad5). Ad5 replicates to 100- to 1000-fold higher titers in STAT2 KO hamsters than in wild-type ones, and this increased infection causes enhanced pathology. However, the adaptive immune response to the virus infection seems to be intact with the STAT2 KO hamsters, and surviving animals clear the virus effectively. The data reported here may be of interest to researchers focusing on adenoviruses, and also to those who utilize the Syrian hamster as their animal model for other purposes.

Vyšlo v časopise: STAT2 Knockout Syrian Hamsters Support Enhanced Replication and Pathogenicity of Human Adenovirus, Revealing an Important Role of Type I Interferon Response in Viral Control. PLoS Pathog 11(8): e32767. doi:10.1371/journal.ppat.1005084
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1005084

Souhrn

Zdroje

1. Berk AJ. Adenoviridae. In: Knipe DM, Howley PM, editors. Fields Virology. Philadelphia, PA: Lippincott williams & Wilkins; 2013. p. 1704–31.

2. Russell WC. Adenoviruses: update on structure and function. J Gen Virol. 2009;90(Pt 1):1–20. doi: 10.1099/vir.0.003087-0 19088268

3. Lion T. Adenovirus infections in immunocompetent and immunocompromised patients. Clin Microbiol Rev. 2014;27(3):441–62. Epub 2014/07/02. doi: 10.1128/CMR.00116-13 24982316

4. Asmuth DM, Brown EL, DiNubile MJ, Sun X, Del Rio C, Harro C, et al. Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens. J Infect Dis. 2010;201(1):132–41. doi: 10.1086/648591 19929694

5. Wold WSM, Ison MG. Adenoviruses. In: Knipe DM, Howley PM, editors. Fields Virology. Philadelphia, PA Lippincott Williams & Wilkins; 2013. p. 1732.

6. Matthes-Martin S, Boztug H, Lion T. Diagnosis and treatment of adenovirus infection in immunocompromised patients. Expert review of anti-infective therapy. 2013;11(10):1017–28. Epub 2013/10/01. doi: 10.1586/14787210.2013.836964 24073835

7. Sandkovsky U, Vargas L, Florescu DF. Adenovirus: current epidemiology and emerging approaches to prevention and treatment. Current infectious disease reports. 2014;16(8):416. Epub 2014/06/09. doi: 10.1007/s11908-014-0416-y 24908344

8. Hendrickx R, Stichling N, Koelen J, Kuryk L, Lipiec A, Greber UF. Innate immunity to adenovirus. Hum Gene Ther. 2014;25(4):265–84. Epub 2014/02/12. doi: 10.1089/hum.2014.001 24512150

9. Fejer G, Drechsel L, Liese J, Schleicher U, Ruzsics Z, Imelli N, et al. Key role of splenic myeloid DCs in the IFN-alphabeta response to adenoviruses in vivo. PLoSPathog. 2008;4(11):e1000208.

10. Nociari M, Ocheretina O, Schoggins JW, Falck-Pedersen E. Sensing infection by adenovirus: Toll-like receptor-independent viral DNA recognition signals activation of the interferon regulatory factor 3 master regulator. J Virol. 2007;81(8):4145–57. 17251283

11. Lam E, Falck-Pedersen E. Unabated adenovirus replication following activation of the cGAS/STING-dependent antiviral response in human cells. J Virol. 2014;88(24):14426–39. Epub 2014/10/10. doi: 10.1128/JVI.02608-14 25297994

12. Lam E, Stein S, Falck-Pedersen E. Adenovirus detection by the cGAS/STING/TBK1 DNA sensing cascade. J Virol. 2014;88(2):974–81. Epub 2013/11/08. doi: 10.1128/JVI.02702-13 24198409

13. Blasius AL, Beutler B. Intracellular toll-like receptors. Immunity. 2010;32(3):305–15. Epub 2010/03/30. doi: 10.1016/j.immuni.2010.03.012 20346772

14. Johnson MJ, Petrovas C, Yamamoto T, Lindsay RW, Lore K, Gall JG, et al. Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity. J Immunol. 2012;188(12):6109–18. Epub 2012/05/16. doi: 10.4049/jimmunol.1103717 22586038

15. Johnson MJ, Bjorkstrom NK, Petrovas C, Liang F, Gall JG, Lore K, et al. Type I interferon-dependent activation of NK cells by rAd28 or rAd35, but not rAd5, leads to loss of vector-insert expression. Vaccine. 2014;32(6):717–24. Epub 2013/12/12. doi: 10.1016/j.vaccine.2013.11.055 24325826

16. Bortolanza S, Bunuales M, Otano I, Gonzalez-Aseguinolaza G, Ortiz-de-Solorzano C, Perez D, et al. Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. MolTher. 2009;17(4):614–22.

17. Cerullo V, Koski A, Vaha-Koskela M, Hemminki A. Chapter eight—Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans. Adv Cancer Res. 2012;115:265–318. Epub 2012/10/02. doi: 10.1016/B978-0-12-398342-8.00008-2 23021247

18. Dhar D, Spencer JF, Toth K, Wold WS. Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model. Molecular therapy: the journal of the American Society of Gene Therapy. 2009;17(10):1724–32. Epub 2009/07/16.

19. Sonabend AM, Ulasov IV, Han Y, Rolle CE, Nandi S, Cao D, et al. Biodistribution of an oncolytic adenovirus after intracranial injection in permissive animals: a comparative study of Syrian hamsters and cotton rats. Cancer Gene Ther. 2009;16(4):362–72. doi: 10.1038/cgt.2008.80 19011597

20. Spencer JF, Sagartz JE, Wold WSM, Toth K. New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster. Cancer Gene Ther. 2009;16(12):912–22. doi: 10.1038/cgt.2009.36 19478829

21. Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K, et al. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res. 2006;66(3):1270–6. 16452178

22. Thomas MA, Spencer JF, Toth K, Sagartz JE, Phillips N, Wold WSM. Immunosuppression enhances oncolytic adenovirus replication and anti tumor efficacy in the Syrian hamster model. Mol Ther. 2008;16:1665–73. doi: doi:10.1038/mt.2008.162 18665155

23. Dhar D, Spencer JF, Toth K, Wold WS. Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters. J Virol. 2009;83(5):2130–9. Epub 2008/12/17. doi: 10.1128/JVI.02127-08 19073718

24. Dhar D, Toth K, Wold WS. Syrian hamster tumor model to study oncolytic Ad5-based vectors. Methods Mol Biol. 2012;797:53–63. Epub 2011/09/29. doi: 10.1007/978-1-61779-340-0_4 21948468

25. Dhar D, Toth K, Wold WS. Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters. Cancer Gene Ther. 2014;21(4):171–8. Epub 2014/04/12. doi: 10.1038/cgt.2014.13 24722357

26. Young BA, Spencer JF, Ying B, Tollefson AE, Toth K, Wold WS. The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors. Cancer Gene Ther. 2013;20(9):521–30. Epub 2013/08/10. doi: 10.1038/cgt.2013.49 23928731

27. Young BA, Spencer JF, Ying B, Toth K, Wold WS. The effects of radiation on antitumor efficacy of an oncolytic adenovirus vector in the Syrian hamster model. Cancer Gene Ther. 2013;20(9):531–7. Epub 2013/08/10. doi: 10.1038/cgt.2013.50 23928730

28. Lichtenstein DL, Spencer JF, Doronin K, Patra D, Meyer J, Shashkova EV, et al. An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector. Cancer Gene Ther. 2009;16:644–54. doi: 10.1038/cgt.2009.5 19197324

29. Ying B, Toth K, Spencer JF, Meyer J, Tollefson AE, Patra D, et al. INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies. Cancer Gene Ther. 2009;16(8):625–37. Epub 2009/02/07. doi: 10.1038/cgt.2009.6 19197322

30. Toth K, Spencer JF, Dhar D, Sagartz JE, Buller RM, Painter GR, et al. Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc Natl Acad Sci U S A. 2008;105(20):7293–7. Epub 2008/05/21. doi: 10.1073/pnas.0800200105 18490659

31. Tollefson AE, Spencer JF, Ying B, Buller RM, Wold WS, Toth K. Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model. Antiviral Res. 2014;112:38–46. Epub 2014/12/03. doi: 10.1016/j.antiviral.2014.10.005 25453340

32. Toth K, Ying B, Tollefson AE, Spencer JF, Balakrishnan L, Sagartz JE, et al. Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed female and male Syrian hamsters. Viruses. 2015;7(3):1409–28. Epub 2015/03/26. doi: 10.3390/v7031409 25807051

33. Ying B, Tollefson AE, Spencer JF, Balakrishnan L, Dewhurst S, Capella C, et al. Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters. Antimicrob Agents Chemother. 2014;58(12):7171–81. Epub 2014/09/17. doi: 10.1128/AAC.03860-14 25224011

34. Fan Z, Li W, Lee SR, Meng Q, Shi B, Bunch TD, et al. Efficient gene targeting in golden Syrian hamsters by the CRISPR/Cas9 system. PloS one. 2014;9(10):e109755. Epub 2014/10/10. doi: 10.1371/journal.pone.0109755 25299451

35. Fink K, Grandvaux N. STAT2 and IRF9: Beyond ISGF3. Jak-Stat. 2013;2(4):e27521. Epub 2014/02/06. doi: 10.4161/jkst.27521 24498542

36. Reich NC. STATs get their move on. Jak-Stat. 2013;2(4):e27080. Epub 2014/01/29. doi: 10.4161/jkst.27080 24470978

37. Park C, Li S, Cha E, Schindler C. Immune response in Stat2 knockout mice. Immunity. 2000;13(6):795–804. 11163195

38. Toth K, Spencer JF, Dhar D, Sagartz JE, Buller RM, Painter GR, et al. Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc Natl Acad Sci U S A. 2008;105(20):7293–7. doi: 10.1073/pnas.0800200105 18490659

39. Kitajewski J, Schneider RJ, Safer B, Munemitsu SM, Samuel CE, Thimmappaya B, et al. Adenovirus VAI RNA antagonizes the antiviral action of interferon by preventing activation of the interferon-induced eIF-2 alpha kinase. Cell. 1986;45(2):195–200. 3698097

40. Thimmappaya B, Weinberger C, Schneider RJ, Shenk T. Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection. Cell. 1982;31(3 Pt 2):543–51. Epub 1982/12/01. 6297772

41. Fish EN, Banerjee K, Levine HL, Stebbing N. Antiherpetic effects of a human alpha interferon analog, IFN-alpha Con1, in hamsters. Antimicrob Agents Chemother. 1986;30(1):52–6. Epub 1986/07/01. 3019238

42. Gonzalez-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nature reviews Immunology. 2012;12(2):125–35. Epub 2012/01/10. doi: 10.1038/nri3133 22222875

43. Biron CA, Nguyen KB, Pien GC. Innate immune responses to LCMV infections: natural killer cells and cytokines. Curr Top Microbiol Immunol. 2002;263:7–27. Epub 2002/05/04. 11987821

44. Fejer G, Freudenberg M, Greber UF, Gyory I. Adenovirus-triggered innate signalling pathways. European journal of microbiology & immunology. 2011;1(4):279–88. Epub 2011/12/01.

45. Muruve DA. The Innate Immune Response to Adenovirus Vectors. Hum Gene Ther. 2004;15(12):1157–66. 15684693

46. Routes JM, Li H, Bayley ST, Ryan S, Klemm DJ. Inhibition of IFN-stimulated gene expression and IFN induction of cytolytic resistance to natural killer cell lysis correlate with E1A-p300 binding. J Immunol. 1996;156(3):1055–61. Epub 1996/02/01. 8557979

47. Ackrill AM, Foster GR, Laxton CD, Flavell DM, Stark GR, Kerr IM. Inhibition of the cellular response to interferons by products of the adenovirus type 5 E1A oncogene. Nucleic Acids Res. 1991;19(16):4387–93. Epub 1991/08/25. 1832217

48. Gutch MJ, Reich NC. Repression of the interferon signal transduction pathway by the adenovirus E1A oncogene. Proc Natl Acad Sci U S A. 1991;88(18):7913–7. Epub 1991/09/15. 1654549

49. Kalvakolanu DV, Bandyopadhyay SK, Harter ML, Sen GC. Inhibition of interferon-inducible gene expression by adenovirus E1A proteins: block in transcriptional complex formation. Proc Natl Acad Sci U S A. 1991;88(17):7459–63. Epub 1991/09/01. 1652751

50. Fonseca GJ, Thillainadesan G, Yousef AF, Ablack JN, Mossman KL, Torchia J, et al. Adenovirus evasion of interferon-mediated innate immunity by direct antagonism of a cellular histone posttranslational modification. Cell host & microbe. 2012;11(6):597–606. Epub 2012/06/19.

51. Anderson KP, Fennie EH. Adenovirus early region 1A modulation of interferon antiviral activity. J Virol. 1987;61:787–95. 3027405

52. Routes JM, Li H, Bayley ST, Ryan SKDJ. Inhibition of IFN-stimulated gene expression and IFN induction of cytolytic resistance to natural killer cell lysis correlate with E1A-p300 binding. JImmunol. 1996;156:1055–61.

53. Look DC, Roswit WT, Frick AG, Gris-Alevy Y, Dickhaus DM, Walter MJ, et al. Direct suppression of Stat1 function during adenoviral infection. Immunity. 1998;9(6):871–80. 9881977

54. Shi L, Ramaswamy M, Manzel LJ, Look DC. Inhibition of Jak1-dependent signal transduction in airway epithelial cells infected with adenovirus. Am J Respir Cell Mol Biol. 2007;37(6):720–8. Epub 2007/07/21. 17641294

55. Chahal JS, Gallagher C, DeHart CJ, Flint SJ. The repression domain of the E1B 55-kilodalton protein participates in countering interferon-induced inhibition of adenovirus replication. J Virol. 2013;87(8):4432–44. Epub 2013/02/08. doi: 10.1128/JVI.03387-12 23388716

56. Chahal JS, Qi J, Flint SJ. The human adenovirus type 5 E1B 55 kDa protein obstructs inhibition of viral replication by type I interferon in normal human cells. PLoS Pathog. 2012;8(8):e1002853. Epub 2012/08/23. doi: 10.1371/journal.ppat.1002853 22912576

57. Ullman AJ, Hearing P. Cellular proteins PML and Daxx mediate an innate antiviral defense antagonized by the adenovirus E4 ORF3 protein. J Virol. 2008;82(15):7325–35. Epub 2008/05/16. doi: 10.1128/JVI.00723-08 18480450

58. Ullman AJ, Reich NC, Hearing P. Adenovirus E4 ORF3 protein inhibits the interferon-mediated antiviral response. J Virol. 2007;81(9):4744–52. Epub 2007/02/16. 17301128

59. Berscheminski J, Wimmer P, Brun J, Ip WH, Groitl P, Horlacher T, et al. Sp100 isoform-specific regulation of human adenovirus 5 gene expression. J Virol. 2014;88(11):6076–92. Epub 2014/03/14. doi: 10.1128/JVI.00469-14 24623443

60. Zhu J, Huang X, Yang Y. Type I IFN signaling on both B and CD4 T cells is required for protective antibody response to adenovirus. J Immunol. 2007;178(6):3505–10. Epub 2007/03/07. 17339445

61. Schnell MA, Zhang Y, Tazelaar J, Gao GP, Yu QC, Qian R, et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther. 2001;3(5 Pt 1):708–22. 11356076

62. Varnavski AN, Calcedo R, Bove M, Gao G, Wilson JM. Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice. Gene Ther. 2005;12(5):427–36. 15647774

63. Freytag SO, Stricker H, Movsas B, Kim JH. Prostate cancer gene therapy clinical trials. Mol Ther. 2007;15(6):1042–52. 17406342

64. Jiang J, Gross D, Nogusa S, Elbaum P, Murasko DM. Depletion of T cells by type I interferon: differences between young and aged mice. J Immunol. 2005;175(3):1820–6. Epub 2005/07/22. 16034124

65. Kamphuis E, Junt T, Waibler Z, Forster R, Kalinke U. Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood. 2006;108(10):3253–61. Epub 2006/07/27. 16868248

66. Toccaceli F, Rosati S, Scuderi M, Iacomi F, Picconi R, Laghi V. Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment. Hepatogastroenterology. 1998;45(23):1748–52. Epub 1998/12/05. 9840140

67. Kawasaki H, Moriyama M, Hirao C, Takahashi T, Naruse N, Kobayashi S, et al. Effects of interferon on the lymphocyte subset in the blood and lymphoid organs in mice. J Interferon Res. 1986;6(5):507–17. Epub 1986/10/01. 2433363

68. Jones N, Shenk T. Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells. Cell. 1979;17:683–9. 476833

69. Schneider RJ, Weinberger C, Shenk T. Adenovirus VAI RNA facilitates the initiation of translation in virus-infected cells. Cell. 1984;37(1):291–8. Epub 1984/05/01. 6722874

70. Scherneck S, Ulrich R, Feunteun J. The hamster polyomavirus—a brief review of recent knowledge. Virus Genes. 2001;22(1):93–101. Epub 2001/02/24. 11210944

71. Zivcec M, Safronetz D, Haddock E, Feldmann H, Ebihara H. Validation of assays to monitor immune responses in the Syrian golden hamster (Mesocricetus auratus). J Immunol Methods. 2011;368(1–2):24–35. doi: 10.1016/j.jim.2011.02.004 21334343

72. Zhang J, Dong Z, Zhou R, Luo D, Wei H, Tian Z. Isolation of lymphocytes and their innate immune characterizations from liver, intestine, lung and uterus. Cellular & molecular immunology. 2005;2(4):271–80. Epub 2005/11/09.